Hjem › Diffust stort B-celle lymfom › Texas
Diffust stort B-celle lymfom kliniske forsøg i Texas
29 studier for Diffust stort B-celle lymfom søger deltagere på steder i Texas.
Byer i Texas
Officiel studietekst (engelsk)
Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL
- Texas Oncology - Central South, Austin
- Texas Oncology - Dallas Fort Worth, Dallas
- MD Anderson Cancer Center, Houston
- og 2 flere
RekruttererFase 2
Alder 18 og opefter · Alle køn · Opdateret 2. okt. 2026 · NCT06500273Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution
- Texas Children's Hospital, Houston
RekruttererObservationsstudie
Alder 0 til 38 · Alle køn · Opdateret 1. okt. 2026 · NCT06131801Loncastuximab and Roflumilast Added to R-CHOP (Lo-(Rituximab and Roflumilast) RR-CHOP) for Naïve High-Risk Diffuse Large B-cell Lymphoma (DLBCL)
- University Hospital System, San Antonio
- University of Texas Health Science Center San Antonio at the Cancer Therapy and Research Center, San Antonio
RekruttererFase 1
Alder 18 og opefter · Alle køn · Opdateret 29. sep. 2026 · NCT06977711A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies
- Md Anderson Cancer Center, Houston
RekruttererFase 1/2
Alder 18 og opefter · Alle køn · Opdateret 28. sep. 2026 · NCT05006716A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)
- Texas Oncology - DFW ( Site 8000), Dallas
- Houston Methodist Cancer Center ( Site 0154), Houston
- Joe Arrington Cancer Research and Treatment Center ( Site 0183), Lubbock
- og 1 flere
RekruttererFase 3
Alder 18 og opefter · Alle køn · Opdateret 25. sep. 2026 · NCT06717347A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)
- Texas Oncology - West Texas ( Site 8008), Amarillo
- Texas Oncology - Central/South Texas ( Site 8006), Austin
- UT Southwestern Medical Center ( Site 0190), Dallas
- og 2 flere
RekruttererFase 2
Alder 18 og opefter · Alle køn · Opdateret 25. sep. 2026 · NCT06890884A Study of LY4584180 in Adult Participants With Previously Treated Blood Cancers
- Texas Oncology - DFW (Sammons CC), Dallas
- Baylor College of Medicine, Houston
RekruttererFase 1
Alder 18 og opefter · Alle køn · Opdateret 22. sep. 2026 · NCT07226843A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )
- University of Texas Southwestern, Dallas
- MD Anderson Cancer Center, Houston
RekruttererFase 1
Alder 18 og opefter · Alle køn · Opdateret 22. sep. 2026 · NCT07101328Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)
- University of Texas MD Anderson Cancer Center ( Site 1007), Houston
RekruttererFase 1/2
6 Months – 25 Years · Alle køn · Opdateret 17. sep. 2026 · NCT06395103A Study to Evaluate INCA036873 in Participants With Advanced Solid Tumors and Hematological Malignancies
- Md Anderson Cancer Center, Houston
RekruttererFase 1
Alder 18 og opefter · Alle køn · Opdateret 15. sep. 2026 · NCT07195916Evaluate Optimization of CRS Profile for Glofit Monotherapy and Glofit+GemOx in R/R Aggressive B-NHL
- Baylor Scott & White Health, Temple
- Texas Oncology - Gulf Coast, The Woodlands
- Texas Oncology- Northeast Texas, Tyler
RekruttererFase 2
Alder 18 og opefter · Alle køn · Opdateret 11. sep. 2026 · NCT06806033Study of Allo-QuadCAR01-T, an Allogeneic CAR-T Targeting CD19/CD20, in Patients With Relapsed or Refractory B-Cell Malignancies
- MD Anderson Cancer Center, Houston
RekruttererFase 1/2
Alder 18 og opefter · Alle køn · Opdateret 28. aug. 2026 · NCT07284433Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell Lymphoma
- Baylor University Medical Center, Dallas
- Texas Transplant Institute, San Antonio
RekruttererFase 1/2
Alder 18 og opefter · Alle køn · Opdateret 25. aug. 2026 · NCT05826535Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
- University of Texas MD Anderson Cancer Center, Houston
RekruttererFase 1/2
Alder 13 til 90 · Alle køn · Opdateret 6. aug. 2026 · NCT06533579Sample Collection for Ongoing Research and Product Evaluation Study - Non-Hodgkin Lymphoma (SCORE-NHL)
- Natera, Inc., Austin
RekruttererObservationsstudie
Alder 18 og opefter · Alle køn · Opdateret 6. aug. 2026 · NCT07750886Lentiviral Gene Therapy (Zamtocabtagene Autoleucel) LTFU
- UT Southwestern Medical Center, Dallas
RekruttererObservationsstudie
Alder 18 og opefter · Alle køn · Opdateret 5. aug. 2026 · NCT06116110A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy
- St. David's South Austin Medical Center, Austin
- University of Texas Southwestern Medical Center, Fort Worth
- MD Anderson Cancer Center, Houston
- og 1 flere
RekruttererFase 3
Alder 18 og opefter · Alle køn · Opdateret 4. aug. 2026 · NCT07188558A Study of APG-3288 in Relapsed/Refractory Blood Cancers
- The University of TX MD Anderson Cancer Center, Houston
RekruttererFase 1
Alder 18 og opefter · Alle køn · Opdateret 30. jul. 2026 · NCT07424833DALY II USA/ MB-CART2019.1 for DLBCL
- UT Southwestern Medical Center, Dallas
- The University of Texas MD Anderson Cancer Center, Houston
- Texas Transplant Institute, San Antonio
RekruttererFase 2
Alder 18 og opefter · Alle køn · Opdateret 13. jul. 2026 · NCT04792489Safety and Efficacy of Epcoritamab With Gemcitabine, Dexamethasone, and Cisplatin (GDP) Salvage Chemotherapy in Relapsed Refractory Large B-cell Lymphoma
- University of Texas Southwestern Medical Center, Dallas
RekruttererFase 2
Alder 18 og opefter · Alle køn · Opdateret 10. jul. 2026 · NCT05852717A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies
- MD Anderson Cancer Center, Houston
RekruttererFase 1
Alder 18 og opefter · Alle køn · Opdateret 2. jul. 2026 · NCT05131022IOMAB-CAR-T Followed by CAR-T Cell Therapy in R/R DLBCL
- University of Texas Southwestern Medical Center, Dallas
RekruttererFase 1/2
Alder 18 og opefter · Alle køn · Opdateret 8. maj 2026 · NCT06768905The OPAL Study: AVM0703 for Treatment of Lymphoid Malignancies
- University of Texas(UT) Southwestern-Children's Medical Center, Dallas
RekruttererFase 1/2
Alder 12 til 95 · Alle køn · Opdateret 15. apr. 2026 · NCT04329728This is a Phase 1 Trial of ZM008, an Anti-LLT1 Antibody, Used as Single Agent Followed by Combination Treatment With Toripalimab in Patients With Advanced Solid Tumors
- NEXT Oncology, Austin, TX 78758
- NEXT Oncology, San Antonio
RekruttererFase 1
Alder 18 og opefter · Alle køn · Opdateret 2. apr. 2026 · NCT06451497A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies
- MD Anderson Cancer Center, Houston
RekruttererFase 1
Alder 18 og opefter · Alle køn · Opdateret 20. mar. 2026 · NCT04830137Study Adding Drugs to Usual Treatment for Large B-Cell Lymphoma That Returned or Did Not Respond to Treatment
- Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center, Houston
- Ben Taub General Hospital, Houston
- University of Texas Health Science Center at San Antonio, San Antonio
RekruttererFase 2
Alder 18 og opefter · Alle køn · Opdateret 20. okt. 2025 · NCT05890352A Study of AC676 for the Treatment of Relapsed/Refractory B-Cell Malignancies
- University of Texas Southwestern Medical Center, Dallas
RekruttererFase 1
Alder 18 og opefter · Alle køn · Opdateret 2. okt. 2025 · NCT05780034A Study of NX-1607 in Adults With Advanced Malignancies
- MD Anderson Cancer Center, Houston
RekruttererFase 1
Alder 18 og opefter · Alle køn · Opdateret 9. sep. 2025 · NCT05107674Safety and Efficacy of KRT-232 in Combination With Acalabrutinib in Subjects With R/R DLBCL or R/R CLL
- UT Southwestern Medical Center, Dallas
RekruttererFase 1/2
Alder 18 og opefter · Alle køn · Opdateret 4. aug. 2022 · NCT04502394Fra ClinicalTrials.gov, data hentet 3. okt. 2026. Hver studie har sine egne kvalifikationskrav; studieteamet afgør, hvem der kan deltage.